If big medtechs are becoming more demanding when evaluating potential takeout targets, the same is true of investors. For the first time, the number of venture funding rounds closed in a year has dropped beneath 200.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,